David Counts

Dr. Counts joined Angle in 2005 from Ben Franklin Technology Partners.
He completed a postdoctoral fellowship at the Roche Institute of Molecular Biology.
Later, he was a faculty member at Washington State University and the University of Vermont, supported by grants.
Dr. Counts initiated research on skin aging at the Gillette Research Institute and later worked at Lilly Research Laboratories and Marion Laboratories on anti-inflammatory compounds, peptide therapeutics and devices.
He later worked to capture early stage university biotechnology discoveries.
He joined Curative Technologies Inc. as Director for Preclinical Research with responsibility for preclinical development studies.
Dr. Counts helped found a company that developed and marketed products for skin care (Avogen).
He joined BTG, a technology transfer organization, as Associate Vice President for Assessment and Evaluation.
He later joined the Ben Franklin Technology Partners of Southeastern Pennsylvania in 2001 as Director of Life Sciences, with responsibility for the Nanotechnology Institute's corporate relations.
He has publications and patents in wound healing, immunology and inflammation.
Dr. Counts has participated in presenting commercial opportunities to corporations, negotiated research contracts and served as a scientific liaison for commercial development.
Dr. Counts received his B.S.
from Tulane and Ph.D.
in Molecular Biology from the Medical College of Georgia.